Form 4: SOPHiA GENETICS Executive Sells Shares for Tax Obligations

President Ross Muken sold 2,800 shares of SOPHiA GENETICS to cover tax withholding obligations related to RSU vesting.

Summary

• Ross Muken, President of SOPHiA GENETICS, sold 2,800 ordinary shares on April 14, 2026.
• The shares were sold at a weighted average price of $4.9597 per share.
• The transaction was executed to satisfy tax withholding obligations resulting from the vesting of restricted stock units (RSUs) on April 2 and 3, 2026.
• The sale was conducted under a pre-established Rule 10b5-1(c) trading plan, indicating the trade was non-discretionary.
• Following the transaction, the reporting person retains beneficial ownership of 682,432 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative to cover tax obligations and was pre-planned.

Positives

• The sale was non-discretionary and executed pursuant to a pre-established Rule 10b5-1(c) trading plan, mitigating concerns regarding insider sentiment.

Negatives

• The transaction represents a reduction in the direct equity stake held by a key executive.

Risks

• Market volatility affecting the share price, as evidenced by the range of $4.75 to $5.16 per share during the transaction.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Management Comments

• The reporting person confirmed the sale was executed to satisfy tax withholding obligations and was not a discretionary trade.

Industry Context

StockSavvy.ai notes that routine sales by executives to cover tax liabilities upon the vesting of equity awards are standard corporate practice and generally do not signal a change in management's outlook on the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a standard governance practice for executives to avoid potential conflicts of interest or accusations of insider trading.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and related to tax obligations.

Next Steps

• None mentioned.

Key Dates

Keywords

SOPHiA GENETICS, SOPH, Insider Trading, Form 4, Rule 10b5-1, Equity Compensation